IOBENGUANE SULFATE I-123 - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for iobenguane sulfate i-123 and what is the scope of patent protection?
Iobenguane sulfate i-123
is the generic ingredient in one branded drug marketed by Ge Healthcare and is included in one NDA. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for IOBENGUANE SULFATE I-123
US Patents: | 0 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
Clinical Trials: | 4 |
Patent Applications: | 2 |
DailyMed Link: | IOBENGUANE SULFATE I-123 at DailyMed |
Recent Clinical Trials for IOBENGUANE SULFATE I-123
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
United Therapeutics | Phase 1 |
New Approaches to Neuroblastoma Therapy Consortium | Phase 1 |
Children's Oncology Group | Phase 3 |
US Patents and Regulatory Information for IOBENGUANE SULFATE I-123
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ge Healthcare | ADREVIEW | iobenguane sulfate i-123 | SOLUTION;INTRAVENOUS | 022290-001 | Sep 19, 2008 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |